Cardiff Oncology (CRDF)
(Real Time Quote from BATS)
$2.36 USD
+0.11 (4.89%)
Updated Jul 22, 2024 02:53 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CRDF 2.36 +0.11(4.89%)
Will CRDF be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CRDF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRDF
Take the Zacks Approach to Beat the Markets: Navios Maritime, Coinbase Global, Virtu Financial in Focus
Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates
CRDF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cardiff Oncology (CRDF) Is a Great Choice for 'Trend' Investors, Here's Why
Cardiff (CRDF) Stock Rallies 194% in a Month: Here's Why
Here's Why Momentum in Cardiff Oncology (CRDF) Should Keep going
Other News for CRDF
Cardiff Oncology to Present at the Jefferies Healthcare Conference
Cardiff Oncology's Onvansertib: A Speculative Buy With Promising Data
Cardiff Oncology to Present at Upcoming Investor Conferences in May
The $5 Phenoms: 3 Cheap Stocks That Could Skyrocket by 2028
Buy Rating Affirmed on Cardiff Oncology as Phase 2 Trial Shows Promise for Accelerated Approval